Related Experiment Video
Updated: May 20, 2025
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
CircBTBD7-420aa Encoded by hsa_circ_0000563 Regulates the Progression of Atherosclerosis and Construction of
Xiongkang Gan1, Boyu Chi1, Xin Zhang1
1Department of Cardiovascular Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Insights
A novel protein, circBTBD7-420aa, shows potential in treating coronary artery disease by inhibiting smooth muscle cell growth. Engineered exosomes carrying this protein offer a targeted therapeutic approach for atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biotechnology
Background:
- Circular RNAs (circRNAs) are implicated in cardiovascular diseases like coronary artery disease (CAD).
- The precise molecular mechanisms underlying circRNA involvement in CAD remain incompletely understood.
- Identifying novel circRNAs and their functions is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To identify and characterize novel circRNAs involved in coronary artery disease.
- To elucidate the functional role of circBTBD7-420aa in human coronary artery smooth muscle cells.
- To develop a targeted delivery system for circBTBD7-420aa for potential therapeutic applications in atherosclerosis.
Main Methods:
- Identification of circBTBD7-420aa encoded by hsa_circ_0000563.
- Investigation of circBTBD7-420aa's effect on human coronary artery smooth muscle cell proliferation and migration.
- Analysis of circBTBD7-420aa's role in regulating SLC3A2 protein levels via the ubiquitin-proteasome pathway.
- Construction of engineered exosomes loaded with circBTBD7-420aa, modified with osteopontin-targeting peptides.
Main Results:
- circBTBD7-420aa was identified as a novel protein associated with coronary artery disease.
- circBTBD7-420aa demonstrated inhibitory effects on the abnormal proliferation and migration of human coronary artery smooth muscle cells.
- The mechanism involves promoting SLC3A2 degradation through the ubiquitin-proteasome pathway.
- Engineered exosomes effectively targeted vascular smooth muscle cells, delivering circBTBD7-420aa.
Conclusions:
- circBTBD7-420aa shows promise in inhibiting the progression of atherosclerosis.
- circBTBD7-420aa represents a potential novel target for the diagnosis and treatment of coronary artery disease.
- Engineered exosomes provide a viable platform for targeted circRNA-based therapy in cardiovascular disease.
Abstract:
Circular RNAs are associated with cardiovascular disease, including coronary artery disease, but the mechanisms have not been completely elucidated. We found a new protein, circBTBD7-420aa, encoded by hsa_circ_0000563. Our results suggest that circBTBD7-420aa may inhibit the abnormal proliferation and migration of human coronary artery smooth muscle cells by promoting SLC3A2 degradation through the ubiquitin-proteasome pathway. In addition, we constructed engineered exosomes loaded with circBTBD7-420aa that can target vascular smooth muscle cells by modifying peptide fragments targeting osteopontin. This study suggests that circBTBD7-420aa may inhibit the progression of atherosclerosis and serve as a new target for the diagnosis and treatment of coronary artery disease.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...